PIRS
Income statement / Annual
Last year (2023), Pieris Pharmaceuticals, Inc.'s total revenue was $42.81 M,
an increase of 65.28% from the previous year.
In 2023, Pieris Pharmaceuticals, Inc.'s net income was -$24.54 M.
See Pieris Pharmaceuticals, Inc.�s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$42.81 M
|
$25.90 M
|
$31.42 M
|
$29.32 M
|
$46.28 M
|
$29.10 M
|
$25.28 M
|
$5.83 M
|
$2.93 M
|
$5.37 M
|
| Cost of Revenue |
$41.80 M |
$2.78 M |
$2.37 M |
$46.53 M |
$55.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$1.01 M |
$23.12 M |
$29.05 M |
-$17.21 M |
-$8.72 M |
$29.10 M |
$25.28 M |
$5.83 M |
$2.93 M |
$5.37 M |
| Gross Profit Ratio |
0.02 |
0.89 |
0.92 |
-0.59 |
-0.19 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$41.80 M
|
$52.98 M
|
$66.66 M
|
$46.53 M
|
$55.00 M
|
$41.49 M
|
$22.29 M
|
$19.70 M
|
$8.24 M
|
$5.60 M
|
| General & Administrative
Expenses |
$16.85 M
|
$16.39 M
|
$16.59 M
|
$16.71 M
|
$18.44 M
|
$18.44 M
|
$17.58 M
|
$8.89 M
|
$8.37 M
|
$6.96 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$16.85 M
|
$16.39 M
|
$16.59 M
|
$16.71 M
|
$18.44 M
|
$18.44 M
|
$17.58 M
|
$8.89 M
|
$8.37 M
|
$6.96 M
|
| Other Expenses |
$13.91 M |
-$8.17 M |
-$3.69 M |
-$3.66 M |
-$26,000.00 |
$1.80 M |
-$2.10 M |
$119,501.00 |
$10,905.00 |
$3,002.00 |
| Operating Expenses |
$72.57 M |
$61.20 M |
$79.56 M |
$63.24 M |
$73.44 M |
$59.93 M |
$39.87 M |
$28.59 M |
$16.61 M |
$12.56 M |
| Cost And Expenses |
$72.57 M |
$61.20 M |
$79.56 M |
$63.24 M |
$73.44 M |
$59.93 M |
$39.87 M |
$28.59 M |
$16.61 M |
$12.56 M |
| Interest Income |
$1.85 M |
$721,000.00 |
$4,000.00 |
$511,000.00 |
$1.71 M |
$1.96 M |
$152,000.00 |
$2,320.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.95 M |
$2,320.00 |
$184,645.00 |
$2.65 M |
| Depreciation &
Amortization |
$1.78 M
|
$2.78 M
|
$2.37 M
|
$2.13 M
|
$1.04 M
|
$570,000.00
|
$369,000.00
|
$361,382.00
|
$307,906.00
|
$366,979.00
|
| EBITDA |
-$22.76 M
|
-$30.50 M
|
-$43.37 M
|
-$31.61 M
|
-$26.12 M
|
-$30.26 M
|
-$14.23 M
|
-$22.40 M
|
-$13.37 M
|
-$6.83 M
|
| EBITDA Ratio |
-0.53 |
-1.36 |
-1.53 |
-1.08 |
-0.56 |
-1.04 |
-0.56 |
-3.9 |
-4.66 |
-1.34 |
| Operating Income Ratio
|
-0.7
|
-1.68
|
-1.65
|
-1.16
|
-0.59
|
-1.06
|
-0.58
|
-3.9
|
-4.67
|
-1.34
|
| Total Other
Income/Expenses Net |
$5.21 M
|
$10.20 M
|
$6.09 M
|
-$3.15 M
|
$1.69 M
|
$3.77 M
|
-$1.95 M
|
$122,000.00
|
-$173,740.00
|
-$2.65 M
|
| Income Before Tax |
-$24.54 M |
-$33.28 M |
-$45.74 M |
-$37.07 M |
-$25.47 M |
-$27.07 M |
-$16.54 M |
-$22.64 M |
-$13.85 M |
-$9.85 M |
| Income Before Tax Ratio
|
-0.57
|
-1.28
|
-1.46
|
-1.26
|
-0.55
|
-0.93
|
-0.65
|
-3.88
|
-4.73
|
-1.84
|
| Income Tax Expense |
$0.00 |
-$2.02 M |
-$2.37 M |
$164,000.00 |
-$1.71 M |
-$312,000.00 |
$1.10 M |
$161,970.00 |
$203,866.00 |
-$18.00 |
| Net Income |
-$24.54 M |
-$31.25 M |
-$43.37 M |
-$37.23 M |
-$23.76 M |
-$26.75 M |
-$17.65 M |
-$22.80 M |
-$14.06 M |
-$9.85 M |
| Net Income Ratio |
-0.57 |
-1.21 |
-1.38 |
-1.27 |
-0.51 |
-0.92 |
-0.7 |
-3.91 |
-4.8 |
-1.84 |
| EPS |
-21.8 |
-33.71 |
-53.75 |
-54.67 |
-37.54 |
-40.32 |
-32.14 |
-43.73 |
-32.7 |
-20.62 |
| EPS Diluted |
-21.8 |
-33.71 |
-53.75 |
-54.67 |
-37.54 |
-40.32 |
-32.14 |
-43.73 |
-32.7 |
-20.62 |
| Weighted Average Shares
Out |
$1.13 M
|
$927,150.00
|
$806,838.00
|
$681,013.00
|
$632,813.00
|
$663,513.00
|
$549,138.00
|
$521,413.00
|
$429,908.00
|
$477,680.00
|
| Weighted Average Shares
Out Diluted |
$1.13 M
|
$927,150.00
|
$806,838.00
|
$681,013.00
|
$632,813.00
|
$663,513.00
|
$549,138.00
|
$521,413.00
|
$429,908.00
|
$477,680.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
